Dysplastic Nevi

Dermatologic Clinics

Volumn 30, Issue 3, 2012, Pages 389-404

  Farber, Michele J ^a   Heilman, Edward R ^b,c   Friedman, Robert J ^d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b SUNY Downstate Medical Center   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytologic atypia; Dysplastic nevi; Genetic mutation; Melanoma

Indexed keywords

FLUOROURACIL; HYDROCORTISONE; IMIQUIMOD; ISOTRETINOIN; RETINOIC ACID; SUNSCREEN;

ANAMNESIS; CANCER RISK; CLINICAL FEATURE; DYSPLASTIC NEVUS; ENVIRONMENTAL FACTOR; EPILUMINESCENCE MICROSCOPY; FAMILY HISTORY; GENE MUTATION; GENETIC COUNSELING; HEREDITY; HISTOPATHOLOGY; HUMAN; LASER SURGERY; MELANOMA; MICROSATELLITE INSTABILITY; MORBIDITY; PATHOGENESIS; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROTECTIVE CLOTHING; REVIEW; SKIN SURGERY; SUNLIGHT PROTECTION;

DIAGNOSIS, DIFFERENTIAL; DYSPLASTIC NEVUS SYNDROME; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 84863865674     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2012.04.004     Document Type: Review

References (128)

1. Clark W.H., Elder D.E., Guerry D., et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984, 15(12):1147-1165.
2. Clark W.H., Ackerman A.B. An exchange of views regarding the dysplastic nevus controversy. Semin Dermatol 1989, 8(4):229-250.
3. Elder D.E. Dysplastic naevi: an update. Histopathology 2010, 56(1):112-120.
4. Naeyaert J.M., Brochez L. Dysplastic nevi. N Engl J Med 2003, 349(23):2233-2240.
5. Tucker M.A., Halpern A., Holly E.A., et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997, 277(18):1439-1444.
6. Clark W.H., Reimer R.R., Greene M., et al. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol 1978, 114(5):732-738.
7. Lynch H.T., Frichot B.C., Lynch J.F. Familial atypical multiple mole-melanoma syndrome. J Med Genet 1978, 15(5):352-356.
8. Elder D.E., Goldman L.I., Goldman S.C., et al. Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer 1980, 46(8):1787-1794.
9. Ackerman A.B., Milde P. Naming acquired melanocytic nevi. Common and dysplastic, normal and atypical, or Unna, Miescher, Spitz, and Clark?. Am J Dermatopathol 1992, 14(5):447-453.
10. Diagnosis and treatment of early melanoma. NIH consensus development conference. January 27-29, 1992. Consens Statement 1992, 10(1):1-25.
11. Frankel K.A. Intraepithelial melanocytic neoplasia: a classification by pattern analysis of proliferations of atypical melanocytes. Am J Dermatopathol 1987, 9(1):80-81.
12. Sina B., Wood C. Atypical melanocytic proliferations. Am J Dermatopathol 1991, 13(3):317-319.
13. Urso C., Giannini A., Bartolini M., et al. Histological analysis of intraepidermal proliferations of atypical melanocytes. Am J Dermatopathol 1990, 12(2):150-155.
14. Tripp J.M., Kopf A.W., Marghoob A.A., et al. Management of dysplastic nevi: a survey of fellows of the American Academy of Dermatology. J Am Acad Dermatol 2002, 46(5):674-682.
15. Crutcher W.A., Sagebiel R.W. Prevalence of dysplastic naevi in a community practice. Lancet 1984, 1(8379):729.
16. Lee G., Massa M.C., Welykyj S., et al. Yield from total skin examination and effectiveness of skin cancer awareness program. Findings in 874 new dermatology patients. Cancer 1991, 67(1):202-205.
17. Nordlund J.J., Kirkwood J., Forget B.M., et al. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res 1985, 45(4):1855-1861.
18. Steijlen P., Bergman W., Hermans J., et al. The efficacy of histopathological criteria required for diagnosing dysplastic naevi. Histopathology 1988, 12(3):289-300.
19. Grob J., Gouvernet J., Aymar D., et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 1990, 66(2):387-395.
20. Holly E.A., Kelly J.W., Shpall S.N., et al. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 1987, 17(3):459-468.
21. Ng P.C., Barzilai D.A., Ismail S.A., et al. Evaluating invasive cutaneous melanoma: is the initial biopsy representative of the final depth?. J Am Acad Dermatol 2003, 48(3):420-424.
22. Bataille V., Grulich A., Sasieni P., et al. The association between naevi and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and Australia. Br J Cancer 1998, 77(3):505-510.
23. Augustsson A., Stierner U., Rosdahl I., et al. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol 1991, 71(6):518-529.
24. Garbe C., Büttner P., Weiß J., et al. Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the central malignant melanoma registry of the German Dermatological Society. J Invest Dermatol 1994, 102(5):700-705.
25. Garbe C., Krüger S., Stadler R., et al. Markers and relative risk in a German population for developing malignant melanoma. Int J Dermatol 1989, 28(8):517-523.
26. Halpern A.C., Guerry D.P., Elder D.E., et al. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma: a case-control study. Arch Dermatol 1991, 127(7):995-999.
27. MacKie R.M., Aitchison T.C., Freudenberger T. Risk factors for melanoma. Lancet 1989, 2(8668):928.
28. Roush G.C., Nordund J.J., Forget B., et al. Independence of dysplastic nevi from total nevi in patients with melanoma and comparison subjects. Cancer Res 1985, 45:1855-1861.
29. Swerdlow A., English J., MacKie R., et al. Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) 1986, 292(6535):1555-1559.
30. MacKie R., McHenry P., Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet 1993, 341(8861):1618-1620.
31. Rigel D.S., Rivers J.K., Friedman R.J., et al. Risk gradient for malignant melanoma in individuals with dysplastic naevi. Lancet 1988, 331(8581):352-353.
32. Schneider J.S., Moore D.H., Sagebiel R.W. Risk factors for melanoma incidence in prospective follow-up: the importance of atypical (dysplastic) nevi. Arch Dermatol 1994, 130(8):1002-1007.
33. Tiersten A., Grin C., Kopf A., et al. Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome. J Dermatol Surg Oncol 1991, 17(1):44-48.
34. Marghoob A.A., Kopf A.W., Rigel D.S., et al. Risk of cutaneous malignant melanoma in patients with 'classic' atypical-mole syndrome: a case-control study. Arch Dermatol 1994, 130(8):993-998.
35. Shors A., Kim S., White E., et al. Dysplastic naevi with moderate to severe histological dysplasia: a risk factor for melanoma. Br J Dermatol 2006, 155(5):988-993.
36. Halpern A.C., Guerry D.P., Elder D.E., et al. A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol 1993, 100:346S-349S.
37. Tucker M.A., Fraser M.C., Goldstein A.M., et al. Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 1993, 100:350S-355S.
38. Skender-Kalnenas T.M., English D.R., Heenan P.J. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?. J Am Acad Dermatol 1995, 33(6):1000-1007.
39. Salopek T.G., Friedman R.J. Dysplastic nevi. Cancer of the skin 2005, 203-219. Saunders, Philadelphia. D.S. Rigel, R.J. Friedman, L.M. Dzubow (Eds.).
40. Salopek T.G., Kopf A.W., Stefanato C.M., et al. Differentiation of atypical moles (dysplastic nevi) from early melanomas by dermoscopy. Dermatol Clin 2001, 19(2):337-345.
41. Kelly J.W., Yeatman J.M., Regalia C., et al. A high incidence of melanoma found in patients with multiple dysplastic naevi using photographic surveillance. Med J Aust 1997, 167:191-194.
42. Hofman-Wellenhof R., Soyer H.P. Atypical (dysplastic) nevus. Color atlas of melanocytic lesions of the skin 2007, 87-96. Springer, New York. H.P. Soyer, G. Argenziano, R. Hofman-Wellenhof (Eds.).
43. Friedman R.J., Farber M.J., Warycha M.A., et al. The 'dysplastic' nevus. Clin Dermatol 2009, 27(1):103-115.
44. Kopf A.W., Friedman R.J., Rigel D.S. Atypical mole syndrome. J Am Acad Dermatol 1990, 22(1):117-118.
45. Crijns M.B., Vink J., Van Hees C.L., et al. Dysplastic nevi: occurrence in first-and second-degree relatives of patients with 'sporadic' dysplastic nevus syndrome. Arch Dermatol 1991, 127(9):1346-1351.
46. De Wit P., Van't Hof-Grootenboer B., Ruiter D., et al. Validity of the histopathological criteria used for diagnosing dysplastic naevi: an interobserver study by the pathology subgroup of the EORTC malignant melanoma cooperative group. Eur J Cancer 1993, 29(6):831-839.
47. Weinstock M.A., Barnhill R.L., Rhodes A.R., et al. Reliability of the histopathologic diagnosis of melanocytic dysplasia. Arch Dermatol 1997, 133(8):953-958.
48. Ackerman A., Mihara I. Dysplasia, dysplastic melanocytes, dysplastic nevi, the dysplastic nevus syndrome, and the relation between dysplastic nevi and malignant melanomas. Hum Pathol 1985, 16(1):87-91.
49. Shea C.R., Vollmer R.T., Prieto V.G. Correlating architectural disorder and cytologic atypia in Clark (dysplastic) melanocytic nevi. Hum Pathol 1999, 30(5):500-505.
50. Pozo L., Naase M., Cerio R., et al. Critical analysis of histologic criteria for grading atypical (dysplastic) melanocytic nevi. Am J Clin Pathol 2001, 115(2):194-204.
51. Arumi-Uria M., McNutt N.S., Finnerty B. Grading of atypia in nevi: correlation with melanoma risk. Mod Pathol 2003, 16(8):764-771.
52. Brochez L., Verhaeghe E., Grosshans E., et al. Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions. J Pathol 2002, 196(4):459-466.
53. Duncan L.M., Berwick M., Bruijn J.A., et al. Histopathologic recognition and grading of dysplastic melanocytic nevi: an interobserver agreement study. J Invest Dermatol 1993, 100:318S-321S.
54. Bale S.J., Chakravarti A., Greene M. Cutaneous malignant melanoma and familial dysplastic nevi: evidence for autosomal dominance and pleiotropy. Am J Hum Genet 1986, 38(2):188-196.
55. Begg C.B., Orlow I., Hummer A.J., et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005, 97(20):1507-1515.
56. Bishop D.T., Demenais F., Goldstein A.M., et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002, 94(12):894-903.
57. Goldstein A.M., Struewing J.P., Chidambaram A., et al. Genotype-phenotype relationships in US melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000, 92(12):1006-1010.
58. Ruiz A., Puig S., Malvehy J., et al. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. J Med Genet 1999, 36(6):490-493.
59. Bishop D.T., Demenais F., Iles M.M., et al. Genome-wide association study identifies 3 loci associated with melanoma risk. Nat Genet 2009, 41(8):920-925.
60. Goldstein A.M., Martinez M., Tucker M.A., et al. Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families. Cancer Epidemiol Biomarkers Prev 2000, 9(9):889-894.
61. Bishop J.A., Wachsmuth R.C., Harland M., et al. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol 2000, 114(1):28-33.
62. Celebi J., Ward K., Wanner M., et al. Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome. Clin Exp Dermatol 2005, 30(1):68-70.
63. Hashemi J., Linder S., Platz A., et al. Melanoma development in relation to non-functional p16/INK4A protein and dysplastic naevus syndrome in Swedish melanoma kindreds. Melanoma Res 1999, 9(1):21-30.
64. Park W.S., Vortmeyer A.O., Pack S., et al. Allelic deletion at chromosome 9p21 (p16) and 17p13 (p53) in microdissected sporadic dysplastic nevus. Hum Pathol 1998, 29(2):127-130.
65. Sini M.C., Manca A., Cossu A., et al. Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma. Br J Dermatol 2008, 158(2):243-250.
66. Lee J.Y., Dong S.M., Shin M.S., et al. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus. Biochem Biophys Res Commun 1997, 237(3):667-672.
67. Perera M.I., Um K., Greene M.H., et al. Hereditary dysplastic nevus syndrome: lymphoid cell ultraviolet hypermutability in association with increased melanoma susceptibility. Cancer Res 1986, 46(2):1005-1009.
68. Jung E.G., Bohnert E., Boonen H. Dysplastic nevus syndrome: Ultraviolet hypermutability confirmed in vitro by elevated sister chromatid exchanges. Dermatologica 1986, 173(6):297-300.
69. Moriwaki S.I., Tarone R.E., Tucker M.A., et al. Hypermutability of UV-treated plasmids in dysplastic nevus/familial melanoma cell lines. Cancer Res 1997, 57(20):4637-4641.
70. Seetharam S., Waters H.L., Seidman M.M., et al. Ultraviolet mutagenesis in a plasmid vector replicated in lymphoid cells from a patient with the melanoma-prone disorder dysplastic nevus syndrome. Cancer Res 1989, 49(21):5918-5921.
71. Abrahams P.J., Houweling A., Cornelissen-Steijger P.D., et al. Impaired DNA repair capacity in skin fibroblasts from various hereditary cancer-prone syndromes. Mutat Res 1998, 407(2):189-201.
72. Salopek T.G., Yamada K., Ito S., et al. Dysplastic melanocytic nevi contain high levels of pheomelanin: quantitative comparison of pheomelanin/eumelanin levels between normal skin, common nevi, and dysplastic nevi. Pigment Cell Res 1991, 4(4):172-179.
73. Hussein M.R., Sun M., Tuthill R.J., et al. Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi. J Cutan Pathol 2001, 28(7):343-350.
74. Rubben A., Bogdan I., Grussendorf-Conen E.I., et al. Loss of heterozygosity and microsatellite instability in acquired melanocytic nevi: towards a molecular definition of the dysplastic nevus. Recent Results Cancer Res 2002, 160:100-110.
75. Birindelli S., Tragni G., Bartoli C., et al. Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma. Int J Cancer 2000, 86(2):255-261.
76. Ahmed A.A., Nordlind K., Hedblad M., et al. Interleukin (IL)-1 alpha- and -1 beta-, IL-6-, and tumor necrosis factor-alpha-like immunoreactivities in human common and dysplastic nevocellular nevi and malignant melanoma. Am J Dermatopathol 1995, 17(3):222-229.
77. Elder D.E., Herlyn M. Antigens associated with tumor progression in melanocytic neoplasia. Pigment Cell Res 1992, (Suppl 2):136-143.
78. Ewanowich C., Brynes R.K., Medeiros L., et al. Cyclin D1 expression in dysplastic nevi: an immunohistochemical study. Arch Pathol Lab Med 2001, 125(2):208-210.
79. Fleming M.G., Howe S.F., Candel A.G. Immunohistochemical localization of cytokines in nevi. Am J Dermatopathol 1992, 14(6):496-503.
80. Lazzaro B., Strassburg A. Tumor antigen expression in compound dysplastic nevi and superficial spreading melanoma defined by a panel of nevomelanoma monoclonal antibodies. Hybridoma 1996, 15(2):141-146.
81. Meier F., Satyamoorthy K., Nesbit M., et al. Molecular events in melanoma development and progression. Front Biosci 1998, 3:D1005-D1010.
82. Moretti S., Martini L., Berti E., et al. Adhesion molecule profile and malignancy of melanocytic lesions. Melanoma Res 1993, 3(4):235-239.
83. Nanney L.B., Coffey R.J., Ellis D.L. Expression and distribution of transforming growth factor-α within melanocytic lesions. J Invest Dermatol 1994, 103(5):707-714.
84. Platz A., Ringborg U., Grafström E., et al. Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma. Melanoma Res 1995, 5(2):101.
85. Wang Y., Rao U., Mascari R., et al. Molecular analysis of melanoma precursor lesions. Cell Growth Differ 1996, 7(12):1733-1740.
86. Pollock P.M., Harper U.L., Hansen K.S., et al. High frequency of BRAF mutations in nevi. Nat Genet 2003, 33(1):19-20.
87. Uribe P., Wistuba I.I., González S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 2003, 25(5):365-370.
88. Yazdi A.S., Palmedo G., Flaig M.J., et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003, 121(5):1160-1162.
89. Weinstock M.A., Brodsky G.L. Bias in the assessment of family history of melanoma and its association with dysplastic nevi in a case-control study. J Clin Epidemiol 1998, 51(12):1299-1303.
90. Schmid-Wendtner M.H., Berking C., Baumert J., et al. Cutaneous melanoma in childhood and adolescence: an analysis of 36 patients. J Am Acad Dermatol 2002, 46(6):874-879.
91. Haley J.C., Hood A.F., Chuang T.Y., et al. The frequency of histologically dysplastic nevi in 199 pediatric patients. Pediatr Dermatol 2000, 17(4):266-269.
92. Robinson J.K., Bigby M. Prevention of melanoma with regular sunscreen use. JAMA 2011, 306(3):302-303.
93. Tucker M.A., Fraser M.C., Goldstein A.M., et al. A natural history of melanomas and dysplastic nevi. Cancer 2002, 94(12):3192-3209.
94. Halpern A.C., Guerry D.P., Elder D.E., et al. Natural history of dysplastic nevi. J Am Acad Dermatol 1993, 29(1):51-57.
95. Rodriguez-Sains R. Ocular findings in patients with dysplastic nevus syndrome. Ophthalmology 1986, 93(5):661-665.
96. Bataille V., Sasieni P., Cuzick J., et al. Risk of ocular melanoma in relation to cutaneous and iris naevi. Int J Cancer 1995, 60(5):622-626.
97. Hurst E.A., Harbour J.W., Cornelius L.A. Ocular melanoma: a review and the relationship to cutaneous melanoma. Arch Dermatol 2003, 139(8):1067-1073.
98. Van Hees C., De Boer A., Jager M., et al. Are atypical nevi a risk factor for uveal melanoma? A case-control study. J Invest Dermatol 1994, 103(2):202-205.
99. Kittler H., Pehamberger H., Wolff K., et al. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002, 3(3):159-165.
100. Argenziano G., Soyer H.P., Chimenti S., et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the internet. J Am Acad Dermatol 2003, 48(5):679-693.
101. Hofmann-Wellenhof R., Blum A., Wolf I.H., et al. Dermoscopic classification of Clark's nevi (atypical melanocytic nevi). Clin Dermatol 2002, 20(3):255-258.
102. Feit N.E., Dusza S.W., Marghoob A.A. Melanomas detected with the aid of total cutaneous photography. Br J Dermatol 2004, 150(4):706-714.
103. Banky J.P., Kelly J.W., English D.R., et al. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol 2005, 141(8):998-1006.
104. Lucas C.R., Sanders L.L., Murray J.C., et al. Early melanoma detection: nonuniform dermoscopic features and growth. J Am Acad Dermatol 2003, 48(5):663-671.
105. Goodson A.G., Grossman D. Strategies for early melanoma detection: approaches to the patient with nevi. J Am Acad Dermatol 2009, 60(5):719-735.
106. Friedman R.J., Gutkowicz-Krusin D., Farber M.J., et al. The diagnostic performance of expert dermoscopists vs a computer-vision system on small-diameter melanomas. Arch Dermatol 2008, 144(4):476-482.
107. Monheit G., Cognetta A.B., Ferris L., et al. The performance of MelaFind: a prospective multicenter study. Arch Dermatol 2011, 147(2):188-194.
108. Kefford R.F., Newton Bishop J.A., Bergman W., et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999, 17(10):3245-3251.
109. Bruno W., Ghiorzo P., Battistuzzi L., et al. Clinical genetic testing for familial melanoma in Italy: a cooperative study. J Am Acad Dermatol 2009, 61(5):775-782.
110. Sober A.J., Chuang T.Y., Duvic M., et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001, 45(4):579-586.
111. Tran K.T., Wright N.A., Cockerell C.J. Biopsy of the pigmented lesion-when and how. J Am Acad Dermatol 2008, 59(5):852-871.
112. Armour K., Mann S., Lee S. Dysplastic naevi: to shave, or not to shave? A retrospective study of the use of the shave biopsy technique in the initial management of dysplastic naevi. Australas J Dermatol 2005, 46(2):70-75.
113. Goodson A.G., Florell S.R., Boucher K.M., et al. Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi. J Am Acad Dermatol 2010, 62(4):591-596.
114. Kmetz E.C., Sanders H., Fisher G., et al. The role of observation in the management of atypical nevi. South Med J 2009, 102(1):45-48.
115. Bondi E.E., Clark W.H., Elder D., et al. Topical chemotherapy of dysplastic melanocytic nevi with 5% fluorouracil. Arch Dermatol 1981, 117(2):89-92.
116. Duke D., Byers H.R., Sober A.J., et al. Treatment of benign and atypical nevi with the normal-mode ruby laser and the Q-switched ruby laser: clinical improvement but failure to completely eliminate nevomelanocytes. Arch Dermatol 1999, 135(3):290-296.
117. Dusza S.W., Delgado R., Busam K.J., et al. Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study. J Drugs Dermatol 2006, 5(1):56-62.
118. Edwards L., Jaffe P. The effect of topical tretinoin on dysplastic nevi: a preliminary trial. Arch Dermatol 1990, 126(4):494-499.
119. Edwards L., Meyskens F., Levine N. Effect of oral isotretinoin on dysplastic nevi. J Am Acad Dermatol 1989, 20(2):257-260.
120. Halpern A.C., Schuchter L.M., Elder D.E., et al. Effects of topical tretinoin on dysplastic nevi. J Clin Oncol 1994, 12(5):1028-1035.
121. Meyskens F.L., Edwards L., Levine N.S. Role of topical tretinoin in melanoma and dysplastic nevi. J Am Acad Dermatol 1986, 15(4):822-825.
122. Somani N., Martinka M., Crawford R.I., et al. Treatment of atypical nevi with imiquimod 5% cream. Arch Dermatol 2007, 143(3):379-385.
123. Stam-Posthuma J., Vink J., Le Cessie S., et al. Effect of topical tretinoin under occlusion on atypical naevi. Melanoma Res 1998, 8(6):539-548.
124. Stratigos A.J., Dover J.S., Arndt K.A. Laser treatment of pigmented lesions-2000: how far have we gone?. Arch Dermatol 2000, 136(7):915-921.
125. Zipser M.C., Mangana J., Oberholzer P.A., et al. Melanoma after laser therapy of pigmented lesions-circumstances and outcome. Eur J Dermatol 2010, 20(3):334-338.
126. Kelly J.W., Rivers J.K., MacLennan R., et al. Sunlight: a major factor associated with the development of melanocytic nevi in Australian schoolchildren. J Am Acad Dermatol 1994, 30(1):40-48.
127. Green A.C., Williams G.M., Logan V., et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011, 29(3):257-263.
128. Gallagher R.P., Rivers J.K., Lee T.K., et al. Broad-spectrum sunscreen use and the development of new nevi in white children: a randomized control trial. JAMA 2000, 283(22):2955-2960.